Drug Approval | April 30, 2026
Wanbury's Patalganga site clears Korea FDA inspection with zero observations
Patalganga plant received zero observation from USFDA earlier
Patalganga plant received zero observation from USFDA earlier
The agreement could rise to $900 million if key commercial milestones are met
Union health minister urges graduates in Chandigarh to combine technological excellence with compassion in medical practice
SRM Medical College Hospital and Research Centre hosts undergraduate research expo highlighting innovation, interdisciplinary collaboration, and the role of artificial intelligence
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
Experts call for integrated, evidence-based approaches to tackle rising dengue, malaria, and chikungunya burden in Indian cities
Subscribe To Our Newsletter & Stay Updated
